273 related articles for article (PubMed ID: 2321777)
21. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
22. Malignant hyperthermia in the otolaryngologic patient: prospective anesthetic and surgical management of eight children.
Dudley JP; Reynolds R; Dubrow TJ
Ann Otol Rhinol Laryngol; 1990 Apr; 99(4 Pt 1):297-9. PubMed ID: 2327699
[TBL] [Abstract][Full Text] [Related]
23. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
Larach MG; Landis JR; Bunn JS; Diaz M
Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
[TBL] [Abstract][Full Text] [Related]
24. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
25. Malignant hyperthermia: a potentially fatal complication of anesthesia.
Stolworthy C; Haas RE
Semin Perioper Nurs; 1998 Jan; 7(1):58-66. PubMed ID: 9510843
[TBL] [Abstract][Full Text] [Related]
26. Malignant hyperthermia.
Ben Abraham R; Adnet P; Glauber V; Perel A
Postgrad Med J; 1998 Jan; 74(867):11-7. PubMed ID: 9538480
[TBL] [Abstract][Full Text] [Related]
27. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Ording H
Acta Anaesthesiol Scand; 1989 Jul; 33(5):405-8. PubMed ID: 2800978
[TBL] [Abstract][Full Text] [Related]
28. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane muscle contractures.
Cosgrove SB; Eisele PH; Martucci RW; Gronert GA
Lab Anim Sci; 1992 Oct; 42(5):482-5. PubMed ID: 1460848
[TBL] [Abstract][Full Text] [Related]
30. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
31. Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine.
Wedel DJ; Gammel SA; Milde JH; Iaizzo PA
Anesthesiology; 1993 Jun; 78(6):1138-44. PubMed ID: 8512107
[TBL] [Abstract][Full Text] [Related]
32. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
[TBL] [Abstract][Full Text] [Related]
33. The association between the neuroleptic malignant syndrome and malignant hyperthermia.
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Adnet-Bonte CA; Saulnier F; Dupuis BA
Acta Anaesthesiol Scand; 1989 Nov; 33(8):676-80. PubMed ID: 2588999
[TBL] [Abstract][Full Text] [Related]
34. In vitro interaction between halothane and succinylcholine in human skeletal muscle: implications for malignant hyperthermia and masseter muscle rigidity.
Fletcher JE; Rosenberg H
Anesthesiology; 1985 Aug; 63(2):190-4. PubMed ID: 4025868
[TBL] [Abstract][Full Text] [Related]
35. [Clinical features of malignant hyperthermia crisis].
Cornet C; Moeller R; Laxenaire MC
Ann Fr Anesth Reanim; 1989; 8(5):435-43. PubMed ID: 2516711
[TBL] [Abstract][Full Text] [Related]
36. Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
Carlson KJ; Sun SA; Swan C; Koenig M; Derkay CS
Int J Pediatr Otorhinolaryngol; 2022 Aug; 159():111187. PubMed ID: 35660936
[TBL] [Abstract][Full Text] [Related]
37. [Abortive course of malignant hyperthermia following preclinical induction of general anesthesia using succinylcholine].
Helf D; Schneiderbanger D; Markus CK; Johannsen S; Schuster F
Anaesthesist; 2018 Apr; 67(4):275-279. PubMed ID: 29480319
[TBL] [Abstract][Full Text] [Related]
38. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
[TBL] [Abstract][Full Text] [Related]
39. Malignant Hyperthermia Susceptibility and Fitness for Duty.
Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
[TBL] [Abstract][Full Text] [Related]
40. [Malignant hyperthermia].
Bouhajja B; Haddad F; Ben Ammar MS
Tunis Med; 2002 Jul; 80(7):395-401. PubMed ID: 12611349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
